Xoran Technologies Submits FDA 510(k) Application for TRON

Xoran Technologies announced the company’s recent submission of an FDA 510(k) application for TRON™, an open-bore fluoroscopy computed tomography (CT) for full-body point-of-care imaging.

The potential new addition to Xoran’s suite of imaging systems offers potential benefits which include reduced transport risks to patients, improved accessibility to patient CT scans in limited spaces, and improved throughput for radiology departments.

With over 20 patents, this FDA 510(k) submission builds on the company’s continued research and development efforts for lung computed tomography (CT) imaging. Those research efforts have shown marked capability in point-of-care CT solutions for the neuro intensive care unit (NICU), the operating room, and satellite stations. The compact, mobile design and engineering of TRON for medical imaging marks a milestone towards optimizing a highly deployable CT scanner, and a point-of-care solution for patients beyond the designated confines of a limited space.

“This addition solidifies our commitment to improving patient accessibility to imaging at the point of care. The benefits of truly mobile compact devices cannot be underscored, and now by engineering the success of our head CT systems into an open-bore system, we are able to drive a new generation of Xoran’s point-of-care (POC) imaging devices,” said Misha Rakic, Xoran CEO.


Other FDA news items can be found here.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.